BNP PARIBAS ASSET MANAGEMENT Holding S.A. Sells 361,764 Shares of CVS Health Co. (NYSE:CVS)

BNP PARIBAS ASSET MANAGEMENT Holding S.A. decreased its holdings in CVS Health Co. (NYSE:CVS) by 62.5% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 217,353 shares of the pharmacy operator’s stock after selling 361,764 shares during the period. BNP PARIBAS ASSET MANAGEMENT Holding S.A.’s holdings in CVS Health were worth $13,667,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Kestra Advisory Services LLC boosted its position in CVS Health by 6.6% during the first quarter. Kestra Advisory Services LLC now owns 174,398 shares of the pharmacy operator’s stock valued at $13,910,000 after purchasing an additional 10,871 shares in the last quarter. Ascent Group LLC grew its position in shares of CVS Health by 503.7% in the 1st quarter. Ascent Group LLC now owns 17,610 shares of the pharmacy operator’s stock worth $1,405,000 after buying an additional 14,693 shares during the last quarter. Zurich Insurance Group Ltd FI bought a new position in shares of CVS Health during the 1st quarter worth approximately $2,114,000. Captrust Financial Advisors lifted its position in CVS Health by 4.9% during the first quarter. Captrust Financial Advisors now owns 1,892,879 shares of the pharmacy operator’s stock valued at $150,976,000 after acquiring an additional 88,113 shares during the last quarter. Finally, Waverly Advisors LLC boosted its stake in CVS Health by 25.0% in the first quarter. Waverly Advisors LLC now owns 14,057 shares of the pharmacy operator’s stock valued at $1,121,000 after acquiring an additional 2,815 shares in the last quarter. Institutional investors own 80.66% of the company’s stock.

CVS Health Stock Up 1.6 %

Shares of CVS stock opened at $58.01 on Friday. The company has a current ratio of 0.80, a quick ratio of 0.59 and a debt-to-equity ratio of 0.80. CVS Health Co. has a twelve month low of $52.71 and a twelve month high of $83.25. The stock has a 50 day moving average of $59.21 and a 200 day moving average of $58.61. The stock has a market cap of $73.00 billion, a P/E ratio of 14.72, a P/E/G ratio of 0.96 and a beta of 0.55.

CVS Health (NYSE:CVS) last posted its earnings results on Wednesday, November 6th. The pharmacy operator reported $1.09 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.08 by $0.01. CVS Health had a net margin of 1.36% and a return on equity of 10.72%. The firm had revenue of $95.43 billion during the quarter, compared to analysts’ expectations of $92.72 billion. During the same period in the previous year, the business posted $2.21 EPS. The business’s revenue was up 6.3% compared to the same quarter last year. As a group, sell-side analysts expect that CVS Health Co. will post 5.43 EPS for the current year.

CVS Health Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, November 1st. Shareholders of record on Monday, October 21st were issued a dividend of $0.665 per share. The ex-dividend date was Monday, October 21st. This represents a $2.66 dividend on an annualized basis and a dividend yield of 4.59%. CVS Health’s payout ratio is currently 67.51%.

Wall Street Analysts Forecast Growth

CVS has been the subject of several analyst reports. TD Cowen upgraded CVS Health from a “hold” rating to a “buy” rating and increased their price objective for the company from $59.00 to $85.00 in a report on Friday, October 4th. Royal Bank of Canada decreased their price target on CVS Health from $68.00 to $58.00 and set an “outperform” rating for the company in a research note on Friday, November 15th. StockNews.com downgraded CVS Health from a “hold” rating to a “sell” rating in a report on Thursday, November 14th. Mizuho decreased their price objective on shares of CVS Health from $73.00 to $66.00 and set an “outperform” rating for the company in a research report on Thursday, October 24th. Finally, Barclays dropped their target price on shares of CVS Health from $75.00 to $71.00 and set an “overweight” rating on the stock in a research report on Thursday, November 7th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and thirteen have given a buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $72.28.

CVS Health Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.